Inland Empire Liver Foundation | Rialto, CA

Research site

(Unclaimed)

Location

2006 North Riverside Avenue Suite A, Rialto, California, United States of America

Site insights

Top conditions

Top treatments

Obeticholic Acid

Ontamalimab

Sofosbuvir

EDP-305

Selonsertib

Emricasan

Rifaximin

Cenicriviroc

Interferon

Daclatasvir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 63 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

Locations recently updated

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling

Non-alcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Nofazinlimab (CS1003)+Lenvatinib

Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting

Crohn's Disease

Drug: Ustekinumab

Drug: Guselkumab Dose 3

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tol...

Enrolling

Chronic Hepatitis B

Drug: RO7565020

Other: Placebo

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes (CENTRICITY)

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting

Nonalcoholic Steatohepatitis (NASH)

Type 2 Diabetes

Drug: Placebo

Drug: HTD1801

RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease (TAHOE)

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RV...

Active, not recruiting

Crohns Disease

Drug: RO7790121

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE)

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting

Cirrhosis

Prevention of Esophageal Varices

Drug: belapectin

Drug: Placebo